[HTML][HTML] Pathogenesis of autoimmune disease

DS Pisetsky - Nature Reviews Nephrology, 2023 - nature.com
Autoimmune diseases are a diverse group of conditions characterized by aberrant B cell
and T cell reactivity to normal constituents of the host. These diseases occur widely and …

C3 glomerulopathy—understanding a rare complement-driven renal disease

RJH Smith, GB Appel, AM Blom, HT Cook… - Nature reviews …, 2019 - nature.com
The C3 glomerulopathies are a group of rare kidney diseases characterized by complement
dysregulation occurring in the fluid phase and in the glomerular microenvironment, which …

[HTML][HTML] KDIGO 2021 clinical practice guideline for the management of glomerular diseases

BH Rovin, SG Adler, J Barratt, F Bridoux… - Kidney …, 2021 - kidney-international.org
Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

Acute glomerulonephritis

S Sethi, AS De Vriese, FC Fervenza - The Lancet, 2022 - thelancet.com
Glomerulonephritis is a heterogeneous group of disorders that present with a combination of
haematuria, proteinuria, hypertension, and reduction in kidney function to a variable degree …

Standardized classification and reporting of glomerulonephritis

S Sethi, FC Fervenza - Nephrology Dialysis Transplantation, 2019 - academic.oup.com
A kidney biopsy is done to determine the etiology of the glomerulonephritis (GN) and the
severity of the lesion, to identify whether other lesions, related to or not related to the GN, are …

[HTML][HTML] Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy-study design of the APPEAR-C3G trial

AS Bomback, D Kavanagh, M Vivarelli, M Meier… - Kidney International …, 2022 - Elsevier
Introduction Complement 3 glomerulopathy (C3G) is a rare kidney disease characterized by
dysregulation of the alternative pathway (AP) of the complement system. About 50% of …

C3 glomerulopathy: ten years' experience at Mayo Clinic

A Ravindran, FC Fervenza, RJH Smith… - Mayo Clinic …, 2018 - Elsevier
Objective To describe the clinicopathological features, complement abnormalities, triggers,
treatment, and outcomes of C3 glomerulopathy. Patients and Methods A total of 114 patients …

Update on C3 glomerulopathy: a complement-mediated disease

F Caravaca-Fontán, L Lucientes, T Cavero, M Praga - Nephron, 2020 - karger.com
Abstract C3 glomerulopathy (C3G) is a clinicopathologic entity secondary to dysregulation of
the alternative complement pathway in plasma and the glomerular microenvironment. The …

Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease

F Caravaca-Fontán… - Clinical Journal of the …, 2020 - journals.lww.com
Results The study group comprised 97 patients (84% C3 glomerulopathy, 16% dense
deposit disease). Forty-two patients were treated with corticosteroids plus MMF, and this …

[HTML][HTML] Association of histologic parameters with outcome in C3 glomerulopathy and idiopathic immunoglobulin-associated membranoproliferative …

HJ Lomax-Browne, NR Medjeral-Thomas… - Clinical Journal of the …, 2022 - journals.lww.com
Results Frequent biopsy features were mesangial expansion and hypercellularity,
glomerular basement membrane double contours, and endocapillary hypercellularity …